FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma

The risks of early death in the trials of Johnson & Johnson and Legend Biotech’s Carvykti and Bristol Myers Squibb and 2seventyBio’s Abcema were not a significant concern for the FDA’s Oncologic Drugs Advisory Committee, which voted 11-0 and 8-3 respectively to support the approvals of the CAR-T therapies as earlier lines of treatment for multiple myeloma.